PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Open Label Extension In Cancer Patients
- Conditions
- NeoplasmsBone Metastases
- Interventions
- Biological: Anti-NGF AB
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT00830180
- Locations
- 🇭🇷
General Hospital Varazdin, Varazdin, Croatia
🇵🇱Hospicjum im Ks Eugeniusza Dutkiewicza SAC w Gdansku, Gdansk, Poland
🇮🇳Central India Cancer Research Institute Central India Cancer Research Institute, Nagpur, Maharashtra, India
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT00828919
- Locations
- 🇮🇹
Fondazione IRCCS, Istituto Nazionale Tumori, S.S.D Oncologia Medica dei Tumori testa-collo, Milano, Italy
🇨🇿Nemocnice Na Bulovce, Praha, Czechia
🇫🇷Hopital de la Pitie Salpetriere, Paris Cedex 13, France
Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery
- Conditions
- Biliary Tract Surgical ProceduresPancreaticoduodenectomyEsophagectomyColectomyGastrectomy
- Interventions
- Drug: Tranexamic acid + Standard of CareProcedure: Standard of Care
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2012-04-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 94
- Registration Number
- NCT00827931
- Locations
- 🇮🇳
Pfizer Investigational Site, Surat, Gujarat, India
Relative Bioavailability and Food Effect Study
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00827515
An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis
- Conditions
- Chronic Prostatitis With Chronic Pelvic Pain Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 62
- Registration Number
- NCT00826514
- Locations
- 🇨🇦
The Male Health Centre, Toronto, Ontario, Canada
🇺🇸Clinical Innovations, Inc., Costa Mesa, California, United States
🇺🇸University Urology, Knoxville, Tennessee, United States
Trulimax (Azithromycin ) Non-Interventional Study In Acute Bacterial Upper Respiratory Tract Infections
- Conditions
- Upper Respiratory Tract Infections
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2011-04-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 421
- Registration Number
- NCT00827502
- Locations
- 🇮🇳
Pfizer Investigational Site, Lucknow, Uttar Pradesh, India
Post-Authorization Study Evaluating Safety Of Tigecycline
- Conditions
- Intra-Abdominal InfectionsSkin Disease, InfectiousSoft Tissues Infections
- Interventions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 115
- Registration Number
- NCT00827541
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
- Conditions
- Alzheimer's DiseaseHuntington's Disease
- Interventions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00827034
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00825084
- Locations
- 🇺🇸
Pfizer Investigational Site, Glendale, California, United States
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children
- Conditions
- Pneumococcal Vaccines
- Interventions
- Biological: 13vPnC
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2011-08-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 234
- Registration Number
- NCT00824655
- Locations
- 🇸🇪
Pfizer Investigational Site, Umea, Sweden